Tenderwize
Wróć do wyszukiwania

Pharmaceutical products for Amgros 2027

Amgros I/S·København Ø, Denmark·DKK 5.1M | EUR 685k·Expired · Aug 20, 2026·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Denmark – Pharmaceutical products – Amgros 2027 1.182.a

63/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkExpired
Skąd ta ocena?

Szansa

63 / 100

Złożoność

45 / 100

Czynniki ryzyka

The structured overall estimated value is DKK 5,120,000, while the XML notice also shows a higher framework maximum amo...

The portal link is present, but no procurement document text was extracted, so detailed contract terms, submission inst...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • DKK 5.1M estimated value
  • Framework procurement
  • Supplies contract
  • 2 lots
  • Duration until Dec 2028
  • Supply of pharmaceutical products under framework agreements for hospital pharmacies in the five Danish regions.
  • Two independent lots for Polatuzumab vedotin (ATC L01FX14) in different strengths.
Pokaż pełne podsumowanie

Open framework-agreement tender by Amgros I/S for pharmaceutical products (CPV 33600000) in Denmark, split into 2 independent lots for Polatuzumab vedotin. Electronic submission is required via the Amgros portal. The notice indicates no minimum suitability requirements and a price-only award criterion. Estimated overall contract value is DKK 5,120,000; the XML also shows a framework maximum amount of DKK 5,738,985, which is higher than the structured overall estimate.

Ryzyka

The structured overall estimated value is DKK 5,120,000, while the XML notice also shows a higher framework maximum amo...

The portal link is present, but no procurement document text was extracted, so detailed contract terms, submission inst...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Open procedure.
  • Framework agreements are non-exclusive and without purchase obligation.

Administrative

  • Electronic submission required.

Kryteria udzielenia

Lot 1

Price (100%, per-exa) — 100%

Lot 2

Price (100%, per-exa) — 100%

Zamawiający

Lokalizacja

København Ø, DNK

Profil zamawiającego

Otwórz profil

Identyfikator

14479880

Działalność

Health

Części (2)

LOT-0001

Polatuzumab vedotin 30 mg infusion solution

Independent framework lot for Polatuzumab vedotin, infusion solution, strength 30 mg, with an estimated quantity of 99 units. The lot is non-exclusive, without purchase obligation, and may be awarded separately from the other lot. Place of performance is Denmark (DK011).

SuppliesFrameworkEU fundedElectronic submission

EUR 685k

Szacowana wartość

Lokalizacja

DK011, Denmark

Czas trwania

Dec 2026 - Dec 2028

Kategoria

Pharmaceutical products

Kryteria udzielenia

Price

Termin

Expired Aug 20, 2026

LOT-0002

Polatuzumab vedotin 140 mg infusion solution

Independent framework lot for Polatuzumab vedotin, infusion solution, strength 140 mg, with an estimated quantity of 117 units. The lot is non-exclusive, without purchase obligation, and may be awarded separately from the other lot. Place of performance is Denmark (DK011).

SuppliesFrameworkEU fundedElectronic submission

EUR 685k

Szacowana wartość

Lokalizacja

DK011, Denmark

Czas trwania

Dec 2026 - Dec 2028

Kategoria

Pharmaceutical products

Kryteria udzielenia

Price

Termin

Expired Aug 20, 2026

Szczegóły zamówienia

Data publikacji
29 Jun 2026
Języki
Danish, Swedish

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
446664-2026

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3